Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us

1

Directories

Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments

Locations

Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana

Psychology Related

Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder

Treatments

Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto

Cities

Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies

Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security

Condition

Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma

Location

    Type Condition

    Munster, IN

    Search
    Munster, IN
    Show Map
    Map View
    Munster, IN

    Search Clinical Trials

    Conditions

    Suggestions

    • Anxiety

    • Depression

    • Alzheimer's Disease

    • Weight Loss

    • Heart Disease

    • Cancer

    • Asthma

    Locations

    Suggestions

      Treatment Type

      Suggestions

      • Cognitive Behavioral Therapy

      • Medication Management

      • Group Therapy

      • Psychotherapy

      • Mindfulness-Based Therapy

      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions

      • Cognitive Behavioral Therapy

      • Medication Management

      • Group Therapy

      • Psychotherapy

      • Mindfulness-Based Therapy

      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      156 Clinical Trials near Munster, IN

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Chemotherapy Combinations for Advanced Pancreatic Cancer

      Munster, Indiana
      This phase II trial compares two treatment combinations: gemcitabine hydrochloride and nab-paclitaxel, or fluorouracil, leucovorin calcium, and liposomal irinotecan in older patients with pancreatic cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine hydrochloride, nab-paclitaxel, fluorouracil, leucovorin calcium, and liposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study may help doctors find out which treatment combination is better at prolonging life in older patients with metastatic pancreatic cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:70+

      Key Eligibility Criteria

      Disqualifiers:Severe Cognitive Impairment, Frail, Others
      Must Not Be Taking:CYP3A4 Inhibitors, UGT1A1 Inhibitors

      176 Participants Needed

      Drug Combinations for Endometrial Cancer

      Munster, Indiana
      This trial tests different drug combinations to treat endometrial cancer that has come back or doesn't respond to usual treatments. The drugs work by either blocking enzymes needed for cancer growth or helping the immune system attack the cancer. The goal is to find the most effective treatment combination.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B/C, Stroke, Others
      Must Not Be Taking:CYP3A Inhibitors, CYP3A4 Inducers

      288 Participants Needed

      Ensifentrine + Glycopyrrolate for COPD

      Hammond, Indiana
      This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Asthma, Lung Cancer, Unstable Cardiac, Others
      Must Be Taking:LABA, LABA/ICS

      480 Participants Needed

      Ensifentrine for Bronchiectasis

      Hammond, Indiana
      This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:COPD, Asthma, Smoking, Others
      Must Not Be Taking:Immunomodulators, CFTR Modulators, PDE4 Inhibitors, Others

      180 Participants Needed

      Dexpramipexole for COPD

      Hammond, Indiana
      This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Asthma, Pulmonary Disease, Infections, Others
      Must Be Taking:ICS-based Therapy

      30 Participants Needed

      CBX-12 for Ovarian Cancer

      Dyer, Indiana
      The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B/C, Others
      Must Not Be Taking:Anticancer, Investigational Agents

      60 Participants Needed

      AZD4604 for Asthma

      Hammond, Indiana
      This trial tests a new asthma medication called AZD4604, which is inhaled regularly using a dry-powder inhaler. It targets adults whose moderate-to-severe asthma is not well-controlled by current treatments. The medication likely works by opening up the airways and reducing inflammation, making it easier to breathe.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe Asthma Exacerbation, COVID-19, Others
      Must Be Taking:ICS, LABA

      340 Participants Needed

      JTT-861 for Heart Failure

      Hammond, Indiana
      This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:30 - 85

      Key Eligibility Criteria

      Disqualifiers:Recent MI, Unstable Angina, Renal Insufficiency, Others
      Must Be Taking:RAAS Inhibitors, Β-blockers

      300 Participants Needed

      Combination Therapy for Non-Hodgkin's Lymphoma

      Munster, Indiana
      This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to tafasitamab and lenalidomide may be able to shrink the cancer or extend the time without cancer symptoms coming back.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:CNS Involvement, MDS, T-LBL, Others
      Must Not Be Taking:BTK Inhibitors, CYP3A Inhibitors

      227 Participants Needed

      Nivolumab +/− Ipilimumab for Endometrial Cancer

      Munster, Indiana
      This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Endometrial Serous Carcinoma, Carcinosarcoma, Active Autoimmune, Others
      Must Not Be Taking:Chronic Steroids, Immunosuppressives

      81 Participants Needed

      Olaparib for Pancreatic Cancer

      Munster, Indiana
      This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Neuroendocrine Tumors, MDS, AML, Others
      Must Not Be Taking:CYP3A4/5 Inhibitors

      152 Participants Needed

      Olaparib Monotherapy vs Combination Therapy for Breast Cancer

      Munster, Indiana
      This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib \[AZD6738\]) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple-negative breast cancer (TNBC) prospectively stratified by presence/absence of qualifying tumour mutation in genes involved in the homologous recombination repair (HRR) pathway. Treatment arms are olaparib monotherapy, olaparib+ Ceralasertib and olaparib+adavosertib. The study subject population will be divided into Stratum A, Stratum B, and Stratum C. Due to the different schedules of administration of each of the treatment options as well as their different toxicity profiles, the study is not blinded. Study has two stage consent process- stage 1 consent (molecular screening for HRR defects) and stage 2 consent (main study). Patients with TNBC and with known qualifying BRCAm, non BRCAm HRRm and non HRRm status will be offered the option of consenting to the main part of the study within the 28-day screening period. Following the ISRC meeting on 17 April 2019 a recommendation was made to close the adavosertib+olaparib treatment arm across all biomarker strata. Patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd). Following the closure of this arm the total number of patients randomised will be lower (approximately 350 patients). Approximately 300 patients will be randomised (using randomisation ratio 1:1) to 2 ongoing treatment arms plus an additional 47 patients to a 3rd arm (olaparib+adavosertib) prior to the arm being discontinued.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Second Primary Cancer, Cardiac Diseases, Hepatitis, Others
      Must Not Be Taking:Parp Inhibitors, Ddr Inhibitors

      273 Participants Needed

      BNT327 + Chemotherapy for Breast Cancer

      Dyer, Indiana
      This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Autoimmune Disease, Heart Conditions, Others
      Must Not Be Taking:Corticosteroids, Antibiotics, Immunosuppressants, Others

      70 Participants Needed

      Redasemtide for Stroke

      Munster, Indiana
      This trial is testing a medication called redasemtide to see if it can help adults who have had a stroke. The goal is to find out if this medication can protect brain cells and help them heal better after the stroke. Researchers are looking at both how well it works and if it is safe to use.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe Consciousness Decrease, Recent Stroke, Others

      849 Participants Needed

      SGN-B6A for Cancer

      Calumet City, Illinois
      This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Neuropathy, ILD, Others
      Must Not Be Taking:Corticosteroids, MMAE Agents

      1006 Participants Needed

      Genetic Testing for Early-Stage Lung Cancer

      Munster, Indiana
      This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Neoadjuvant Therapy, Metastatic Cancer, Pregnancy, Others
      Must Not Be Taking:EGFR Inhibitors, ALK Inhibitors, PD-1/PD-L1 Inhibitors, CTLA-4 Inhibitors

      8300 Participants Needed

      Speak Up! Video for Diabetes

      Chicago Heights, Illinois
      Type 2 diabetes is a significant condition in VA affecting 20% of VA patients. Adherence to medication regimens and lifestyle factors is important to achieve care goals for these patients. Patients who use active participatory communication behaviors with their providers have better adherence to treatment and better biomedical outcomes, yet many patients are not prepared to engage in active communication with their providers. Existing coaching interventions have not been adopted in practice because of the cost of trained personnel. The investigators have shown the efficacy of a low-cost video that did not require trained personnel. This proposal proposes to test implementation strategies to deliver that video in VA primary care clinics and to test the effectiveness of the video to improve outcomes in a Hybrid Type 2 effectiveness-implementation trial using a cluster randomized stepped wedge design at eight sites. This proposal will test feasibility of implementing the video and if successful will generate the evidence to justify widespread dissemination of the video.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Dementia, Terminal Condition, Others

      512 Participants Needed

      5-Year vs. 10-Year Colonoscopy for Colorectal Cancer Prevention

      Munster, Indiana
      This trial aims to determine the best schedule for preventing small, non-dangerous growths in the colon from turning into cancer by regularly checking and removing them.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:45 - 70

      Key Eligibility Criteria

      Disqualifiers:Colorectal Cancer, Inflammatory Bowel Disease, Others

      9500 Participants Needed

      coflex® Interlaminar Stabilization for Spinal Stenosis

      Munster, Indiana
      This trial evaluates the safety and effectiveness of the coflex® device for patients with spinal stenosis and low back pain. The device is a small implant that helps stabilize the spine and relieve nerve pressure. The study aims to see how well it works over an extended period. The Coflex device has been studied extensively for its effectiveness in treating lumbar spinal stenosis and degenerative lumbar diseases, with multiple studies showing its long-term efficacy and safety.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Osteoporosis, Morbid Obesity, Infection, Others

      300 Participants Needed

      Bare Temporary Spur Stent System for Peripheral Arterial Disease

      Munster, Indiana
      This is a prospective, multicenter, single arm study designed to evaluate the safety and efficacy of the Temporary Bare Spur Stent System (Spur Stent System).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Infection, Heart Failure, Renal Impairment, Others
      Must Not Be Taking:Antiplatelets, Anticoagulants, Heparin

      130 Participants Needed

      Why Other Patients Applied

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Trial

      Neovasc Reducer for Refractory Angina

      Munster, Indiana
      This trial tests the Reducer system, a device to improve heart blood flow, in patients with severe chest pain not relieved by standard treatments and unsuitable for surgery. The device works by redirecting blood flow to needy heart areas by narrowing a vein. The Reducer system has been shown to improve chest pain symptoms and heart function in patients with persistent chest pain.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Recent ACS, Uncontrolled Hypertension, Severe COPD, Others
      Must Be Taking:Anti-anginal Agents

      380 Participants Needed

      Guided Physiologic Stenting for Coronary Artery Disease

      Munster, Indiana
      This trial compares two methods for guiding a heart procedure called PCI. It targets patients who need this procedure. One method uses X-ray images, and the other uses pressure measurements to help doctors see where to work during the procedure.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:STEMI, Prior CABG, Cardiogenic Shock, Others

      3212 Participants Needed

      Orbital Atherectomy vs. Angioplasty for Coronary Artery Disease

      Munster, Indiana
      This trial will compare a high-speed rotating device to remove hard calcium deposits with a traditional method for patients with severely calcified artery issues before placing special stents. The new device is designed to help treat these calcified areas.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Heart Failure, Stroke, Others
      Must Not Be Taking:Chemotherapy, Antiplatelets, Anticoagulants, Others

      2005 Participants Needed

      MRI + Mammography for Breast Cancer Screening

      Munster, Indiana
      This randomized phase II trial studies how well abbreviated breast magnetic resonance imaging (MRI) and digital tomosynthesis mammography work in detecting cancer in women with dense breasts. Abbreviated breast MRI is a low cost procedure in which radio waves and a powerful magnet linked to a computer and used to create detailed pictures of the breast in less than 10 minutes. These pictures can show the difference between normal and diseased tissue. Digital tomosynthesis mammography is a procedure that uses multiple x-rays pictures of each breast to produce a 3-dimensional rendering of the entire breast. Combined screening with abbreviated breast MRI and digital tomosynthesis mammography may be a better method to screen women with dense breasts.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:40 - 75
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breast Cancer, High-risk, Others
      Must Not Be Taking:Chemoprevention

      1516 Participants Needed

      Thrombectomy System for Blood Clots in Lungs

      Munster, Indiana
      To evaluate the safety and efficacy of the Cleaner™ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, Stroke, Cancer, Others
      Must Not Be Taking:TPA, Anticoagulants

      125 Participants Needed

      Letrozole for Hormone Receptor-Positive Breast Cancer

      Munster, Indiana
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      3966 Participants Needed

      Lorundrostat for High Blood Pressure

      Munster, Indiana
      This trial tests lorundrostat, a medication that lowers blood pressure by blocking an enzyme involved in hormone production. It targets patients with high blood pressure not controlled by 2 to 5 other medications.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:19+
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1083 Participants Needed

      Vericiguat for Heart Failure

      Munster, Indiana
      The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      6105 Participants Needed

      Chemotherapy + Bevacizumab for Non-Small Cell Lung Cancer

      Munster, Indiana
      This randomized phase III trial studies chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether chemotherapy is more effective with or without bevacizumab in treating non-small cell lung cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1501 Participants Needed

      ClotTriever vs Anticoagulation for Deep Vein Thrombosis

      Munster, Indiana
      This trial compares the effectiveness of the ClotTriever System, which removes blood clots from veins, to standard blood-thinning medication in patients with symptomatic blood clots in one leg. The ClotTriever System, developed by Inari Medical, is a mechanical device used to treat deep vein thrombosis (DVT) by removing blood clots from veins.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      300 Participants Needed

      123456

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials in Indiana

      Anxiety Clinical Trials in Indiana

      Schizophrenia Clinical Trials in Indiana

      ADHD Clinical Trials in Indiana

      Bipolar Disorder Clinical Trials in Indiana

      Multiple Sclerosis Clinical Trials in Indiana

      Autism Clinical Trials in Indiana

      Treatment Resistant Depression Clinical Trials in Indiana

      Borderline Personality Disorder Clinical Trials in Indiana

      Social Anxiety Disorder Clinical Trials in Indiana

      Parkinson's Disease Clinical Trials in Indiana

      Alzheimer's Disease Clinical Trials in Indiana

      By Location

      Clinical Trials near Indianapolis, IN

      Clinical Trials near South Bend, IN

      Clinical Trials near Fort Wayne, IN

      Clinical Trials near Evansville, IN

      Clinical Trials near Elkhart, IN

      Clinical Trials near Mishawaka, IN

      Clinical Trials near Michigan City, IN

      Clinical Trials near Richmond, IN

      Clinical Trials near Carmel, IN

      Clinical Trials near Lafayette, IN

      Clinical Trials near Munster, IN

      Clinical Trials near Muncie, IN

      Other People Viewed

      By Subject

      15 Post-Traumatic Stress Disorder Trials near Philadelphia, PA

      187 Clinical Trials near Gretna, LA

      Top Intrahepatic Cholangiocarcinoma Clinical Trials

      Top Clinical Trials near Castle Rock, CO

      Top Kidney Stone Clinical Trials

      142 Clinical Trials near Dearborn Heights, MI

      77 Arthritis Trials near Los Angeles, CA

      Top Clinical Trials near Decatur, IL

      Top Clinical Trials near Fort Lauderdale, FL

      Top Clinical Trials near Danville, KY

      Top Clinical Trials near Edmonds, WA

      24 Post-Traumatic Stress Disorder Trials near Anaheim, CA

      By Trial

      Topical Estrogen for Transgender Men Undergoing Hysterectomy

      Acceptance and Commitment Therapy for Chronic Post-Surgical Pain

      TILs + Interleukin-2 + Cyclophosphamide for High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

      Cancer Vaccine Combo for Multiple Myeloma

      Pharmacist-Led Access to Medications for Opioid Use Disorder

      Live Donor Champion Program for Liver Disease

      Personalized Hearing Aid Settings for Hearing Loss

      AG-348 for Thalassemia

      DSP107 + Atezolizumab for Colorectal Cancer

      Radiation + Durvalumab for Lung Cancer

      Mavacamten for Hypertrophic Cardiomyopathy

      Divarasib + Pembrolizumab for Non-Small Cell Lung Cancer

      Frequently Asked Questions

      How much do clinical trials in Munster, IN pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Munster, IN work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Munster, IN 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Munster, IN is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Munster, IN several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Munster, IN?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Munster, IN?

      Most recently, we added Orforglipron for Peripheral Artery Disease, Linaprazan Glurate vs Lansoprazole for Acid Reflux and Olpasiran for Cardiovascular Disease to the Power online platform.